Published on May 3, 2025 Antibody-drug conjugates (ADCs) have revolutionized oncology, offering targeted cancer treatments that minimize harm to healthy…
Browsing: Enhertu
FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in Treatment Published: February 20, 2025 On…
The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU®…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Cristian Massacesi, MD, Senior Vice President, Head of…